2-甲基异烟酰盐酸盐 | 554420-32-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-甲基异烟酰盐酸盐
• 英文名称: 2-methylisonicotinoyl chloride hydrochloride
• 英文别名: 2-Methyl-isonicotinoyl chloride hydrochloride；2-methylpyridine-4-carbonyl chloride;hydrochloride
• CAS: 554420-32-5
• 化学式: C₇H₆ClNO*ClH
• 分子量: 192.045
• InChiKey: RIJMUIIPTVKLFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.19
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  30
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-甲基异烟酰盐酸盐 在 盐酸 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 73.0h， 生成 7,7-Dimethyl-2-(2-methylpyridin-4-yl)-1,5-dihydropyrrolo[2,3-f]benzimidazol-6-one
  参考文献：
  名称：

  Nonsteroidal cardiotonics. 1. 2-Pyridyl-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones, a novel class of cardiotonic agents

  摘要：

  A series of substituted 2-pyridyl-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones 1-24 were synthesized and evaluated for positive inotropic activity. In rats, cats, and dogs most of these tricyclic heterocycles produced a dose-related increase in myocardial contractility with little effect on heart rate and blood pressure. The increase in contractility was not mediated via stimulation of beta-adrenergic receptors. Compound 1 (BM 14.478) was more potent than milrinone (25) and enoximone when administered intravenously to rats, cats, and dogs. After oral administration of 1 mg/kg, compound 1, milrinone, and pimobendan were equipotent. However, only 1 and pimobendan were still active after 6 h. The structural requirements necessary for optimal cardiotonic activity within this novel class of heterocycles were investigated.

  DOI：

  10.1021/jm00391a004
• 作为产物：
  描述：

  2-甲基-4-吡啶羧酸甲酯 在 氢氧化钾 、 氯化亚砜 作用下， 生成 2-甲基异烟酰盐酸盐
  参考文献：
  名称：

  实验性结核菌糖化学III。衍生物2-甲基-异烟酸酯

  摘要：

  合成了约52个2-甲基异烟酸酰肼衍生物，并测试了它们的抗结核作用。通过2-甲基异烟酰胺酰肼与醛，酮和羧酸氯化物的反应，通过2-甲基异烟酰胺酰氯与二烷基化肼的缩合，以及2-甲基异烟碱酰肼的氢化来制备衍生物。

  DOI：

  10.1002/hlca.19550380425

文献信息

• [EN] AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMIDO THIADIAZOLE UTILISÉS EN TANT QU'INHIBITEURS DE NADPH OXYDASE
  申请人：GENKYOTEX SA

  公开号：WO2016098005A1

  公开（公告）日：2016-06-23

  The present invention is related to amino thiazole derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式（I）的氨基噻唑衍生物，其药物组合物以及它们在治疗和/或预防与尼古丁胺腺嘌呤二核苷酸磷酸氧化酶（NADPH氧化酶）相关的疾病或症状中的应用。
• Imidazo-benzothiazoles
  申请人：——

  公开号：US20040229862A1

  公开（公告）日：2004-11-18

  The invention relates to 2-imidazo-benzothiazoles of general formula 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R′, R″, X, R′″ and n are defined herein, or a pharmaceutically acceptable salt thereof. It has been found that the compound of formula I are adenosine receptor ligands with good affinity to the A 1 and A 3 receptors. These compounds have useful pharmaceutical activities.

  这项发明涉及一般公式1中的2-咪唑-苯并噻唑，其中R1、R2、R3、R4、R5、R6、R7、R′、R″、X、R′″和n在此处有定义，或其药用可接受的盐。已发现公式I的化合物是与A1和A3受体具有良好亲和力的腺苷受体配体。这些化合物具有有用的药用活性。
• 7-Amino-benzothiazole derivatives
  申请人：——

  公开号：US20030153566A1

  公开（公告）日：2003-08-14

  The present invention relates to compounds of the formula 1 wherein R 1 , R 2 and R 3 are as described herewithin. The compounds of formula I have been found to be adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A 2A -receptor and they are therefore useful in the treatment of diseases, related to this receptor.

  本发明涉及式1的化合物，其中R1、R2和R3如本文所述。发现本发明的化合物具有腺苷受体配体的特性。具体来说，本发明的化合物对A2A受体具有良好的亲和力，因此在治疗与该受体相关的疾病方面是有用的。
• Cyclization process for substituted benzothiazole derivatives
  申请人：——

  公开号：US20040138465A1

  公开（公告）日：2004-07-15

  The present invention relates to a process for preparation of amino substituted benzothiazole derivatives of formula I 1 wherein R 1 , R 2 and R 3 are independently from each other hydrogen, lower alkyl, lower alkoxy or halogen; R 4 is hydrogen, lower alkyl, lower alkyloxy, halogen, or is a five or six membered non aromatic heterocyclyl group, unsubstituted or substituted by lower alkyl or an oxo-group, or is —NR 5 R 6 , wherein R 5 and R 5 are independently from each other hydrogen, lower alkyl, —C(O)-lower alkyl, —(CH 2 ) n O-lower alkyl or benzyl, opionally substituted by lower alkyl, or is an five or six membered heteroaryl group; R 1 and R 2 or R 2 and R 3 may form together with the corresponding carbon atoms a ring containing —O—CH 2 —O— or —CH═CH—CH═CH—; R is hydrogen or —C(O)R′; R′ is a five or six membered non aromatic heterocyclyl group, five or six membered heteroaryl group or is aryl, which rings may be substituted by the groups, selected from lower alkyl, halogen-lower alkyl, lower alkoxy, cyano, nitro, —C(O)H, —C(O)OH or by pyrrolidin- 1 -yl-methyl; n is 1 to 4; or a pharmaceutically acceptable salt thereof, wherein the cyclization is carried out by the treatment of a compound of formula 2 with sulphoxide/HBr/solvent to give the desired products of formula I for R is hydrogen (formula IA) or for R is —C(O)R′ (formula IB) 3

  本发明涉及一种制备式I1的氨基取代苯并噻唑衍生物的方法，其中R1、R2和R3分别独立地为氢、低烷基、低烷氧基或卤素；R4为氢、低烷基、低烷氧基、卤素，或为未取代或取代的五元或六元非芳香杂环基，取代基为低烷基或氧代基，或为—NR5R6，其中R5和R6独立地为氢、低烷基、—C（O）-低烷基、—（CH2）nO-低烷基或苄基，可选地取代为低烷基，或为五元或六元杂环芳基基团；R1和R2或R2和R3可与相应的碳原子一起形成含有—O—CH2—O—或—CH═CH—CH═CH—的环；R为氢或—C（O）R′；R′为五元或六元非芳香杂环基、五元或六元杂环芳基基团或为芳基，这些环可以被从低烷基、卤素-低烷基、低烷氧基、氰基、硝基、—C（O）H、—C（O）OH或吡咯烷-1-基甲基中选择的基取代；n为1至4；或其药学上可接受的盐，其中通过使用硫醇氧化物/HBr/溶剂处理式2的化合物进行环化反应，从而得到所需的式I的产物，其中R为氢（式Ia）或R为—C（O）R′（式Ib）3。
• 7-phenyl-benzo [b] thiophen amide derivatives
  申请人：——

  公开号：US20030149030A1

  公开（公告）日：2003-08-07

  A compound of the formula 1 Compounds of formula I have a good affinity to the A2A receptor and are useful for the treatment of diseases mediated by this receptor.

  该化合物的化学式为1。化学式为I的化合物对A2A受体具有良好的亲和力，可用于治疗由该受体介导的疾病。